<DOC>
	<DOCNO>NCT01528488</DOCNO>
	<brief_summary>The epidermal growth factor receptor ( EGFR ) become important target cancer therapy , small molecular tyrosine kinase inhibitor ( EGFR-TKIs ) play important role treatment non-small cell lung cancer ( NSCLC ) . What accompany encourage efficacy NSCLC common side effect , common one specific papular pustular acne-like rash affect mainly face , scalp , upper torso . But till , medicament prove effective enough treat prevent EGFR-TKIs associated rash . The EVOZAC® Calming Skin Spray show acceptable activity rash prevention preliminary study , investigator conduct randomize , double-blind , control trial evaluate efficacy safety EVOZAC® Calming Skin Spray prevention EGFR-TKIs associate rash NSCLC .</brief_summary>
	<brief_title>Prophylactic EVOZAC® Calming Skin Spray EGFR-TKIs Associated Rash Eruption NSCLC</brief_title>
	<detailed_description>Not suitable : information need described .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically proven NSCLC diagnosis Life expectancy four week absolute neutrophil count ≥ 2.0X109/L , Pt ≥ 100X109/L , hemoglobin ≥ 90g/l With normal hepatic function ( AST , ALT &lt; 2.5 x upper limit normal , Total bilirubin ≤ upper limit normal ) Suitable EGFRTKIs treatment expectant duration four week No specific therapy receive within 4 week prior enrollment may induce similar skin reaction , Cetuximab , Sorafenib , Avastin . With preexist peripheral neuropathy ( National Cancer Institute Common Toxicity Criteria Adverse Events [ NCICTC ] grade ≥ 3 ) No concomitant therapy refer face skin study Signed date informed consent Performance status ≥ 3 ( ECOG ) Pregnant breastfeed patient The lesion count ca n't evaluate due concomitant disease condition Not suitable EGFRTKIs treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>